慢性粒细胞白血病患者停用酪氨酸激酶抑制剂的研究现状

Research status of tyrosine kinase inhibitors discontinuation in patients with chronic myelogenous leukemia

酪氨酸激酶抑制剂(TKI)的临床应用极大延长了慢性粒细胞白血病(CML)患者的生存期,然而长期药物治疗带来的药物不良反应、药物耐药性或不耐受及经济压力等问题使一部分患者无法坚持治疗。目前国外临床试验提示获得深度分子学反应的CML患者停药后可以维持无治疗缓解,文章对CML停用TKI的研究现状进行综述。

The clinical applications of tyrosine kinase inhibitors(TKI)greatly prolong the survival of patients with chronic myelogenous leukemia(CML).However,many problems such as drug side effects,drug resistance or intolerance and economic stress caused by long-term drug treatment have prevented a considerable number of patients from adhering to treatment.At present,a number of clinical trials have suggested that CML patients with stable deep molecular response can achieve treatment-free remission.This article reviews the current research status of discontinuation of TKI in patients with CML.